

Roy S Herbst

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11983378/roy-s-herbst-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

256
papers

44,044
citations

85
h-index

209
g-index

273
ext. papers

51,701
ext. citations

9.6
avg, IF

7.45
L-index

#	Paper	IF	Citations
256	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma 2022 , 10, e003956		0
255	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer 2022 , 10, e004440		1
254	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	11
253	A Burned-Out CD8 T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. <i>Cancer Discovery</i> , 2021 , 11, 1700-1715	24.4	21
252	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , 2021 , 17, e1821-e1829	2.3	1
251	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. <i>Clinical Lung Cancer</i> , 2021 , 22, 187-194.e1	4.9	3
250	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 625-644	19.4	23
249	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1872-1882	8.9	16
248	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 289-298	8.9	12
247	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021 , 22, 178-186	4.9	1
246	A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , 2021 , 22, 170-177	4.9	11
245	Toward personalized treatment approaches for non-small-cell lung cancer. <i>Nature Medicine</i> , 2021 , 27, 1345-1356	50.5	43
244	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) 2021 , 9,		5
243	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100205	1.4	6
242	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1368-1377	13.4	6
241	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1718-1732	8.9	32
240	PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. <i>Clinical Cancer Research</i> , 2020 , 26, 4186-4197	12.9	18

239	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 655-663	21.7	165
238	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 914-947	8.9	71
237	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1580-1590	2.2	104
236	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020 , 383, 1328-1339	59.2	317
235	Frontline immunotherapy for NSCLC - the tale of the tail. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 73-74	19.4	22
234	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. <i>Lancet Oncology, The</i> , 2020 , 21, 1589-1601	21.7	26
233	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020 , 12,	6.6	8
232	Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 1711-1723	59.2	335
231	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. <i>Clinical Cancer Research</i> , 2020 , 26, 970-977	12.9	83
230	Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. <i>Clinical Cancer Research</i> , 2020 , 26, 4360-4368	12.9	32
229	Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for Fusions. <i>Frontiers in Medicine</i> , 2020 , 7, 562480	4.9	2
228	SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1847-1852	8.9	38
227	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1839-1846	8.9	31
226	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1046-1060	8.9	28
225	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 793-801	8.9	28
224	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. <i>Clinical Cancer Research</i> , 2019 , 25, 4663-4673	12.9	102
223	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019 , 25, 4592-4602	14.9	241
222	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. <i>Nature Medicine</i> , 2019 , 25, 656-666	50.5	235

221	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) 2019 , 7, 65		54
220	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1109-1123	21.7	113
219	SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1853-1859	8.9	33
218	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 2084-2096	8.9	27
217	Challenges and approaches to implementing master/basket trials in oncology. <i>Blood Advances</i> , 2019 , 3, 2237-2243	7.8	8
216	Treatment of Advanced Non-Small Cell Lung Cancer in 2018. <i>JAMA Oncology</i> , 2018 , 4, 569-570	13.4	60
215	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018 , 553, 446-454	50.4	1499
214	Immune Checkpoint Inhibition in Lung Cancer 2018 , 333-344		
213	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 210-216	13.4	277
212	Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2018 , 24, 1872-1880	12.9	181
211	ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. <i>Clinical Lung Cancer</i> , 2018 , 19, e533-e536	4.9	48
210	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 831-839	8.9	57
209	Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 469-477	27.4	72
208	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018 , 101, 201-209	7.5	36
207	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) 2018 , 6, 75		107
206	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018 , 23, 1407-e136	5.7	91
205	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 33995-34008	3.3	5
204	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 1562-1573	12.9	93

203	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. <i>Lancet Oncology, The</i> , 2018 , 19, 101-114	21.7	45
202	Management of Advanced NonSmall Cell Lung Cancer 2018 , 99-115		1
201	Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?. <i>Cancer</i> , 2018 , 124, 4592-4596	6.4	6
200	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018 , 39, 624-631	14.4	101
199	Cancer of the Lung 2017 , 1-30		0
198	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1661-1670	10.2	38
197	Immunotherapy in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 131-141	3.1	26
196	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2017 , 23, 5202-5209	12.9	65
195	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5489-5501	12.9	41
194	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017 , 7, 1420-1435	24.4	302
193	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2234-2245	6.1	41
192	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	62
191	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting 2017 , 5,		8
190	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 370-378	12.9	101
189	A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9054-9054	2.2	9
188	Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9055-9055	2.2	11
187	A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9056-9056	2.2	7
186	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 102-102	2.2	17

185	A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 349-349	2.2	17
184	Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. <i>Statistics in Biosciences</i> , 2016 , 8, 99-128	1.5	16
183	Diminished but not dead: chemotherapy for the treatment of NSCLC. <i>Lancet Oncology, The</i> , 2016 , 17, 1464-1465	21.7	14
182	Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1430-1468	7.3	76
181	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 976-983	21.7	666
180	Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3713-72.9	4.9	49
179	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1540-1550	40	3964
178	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 613-638	8.9	164
177	Immune checkpoint therapy for non-small-cell lung cancer: an update. <i>Immunotherapy</i> , 2016 , 8, 279-98	3.8	50
176	Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. <i>Clinical Cancer Research</i> , 2016 , 22, 1907-13	12.9	39
175	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. <i>Clinical Cancer Research</i> , 2016 , 22, 2102-4	12.9	26
174	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3638-3647	2.2	108
173	E2F8 as a Novel Therapeutic Target for Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	62
172	EGFR tyrosine kinase inhibitors in squamous cell lung cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 872-3	21.7	7
171	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. <i>Cancer Discovery</i> , 2015 , 5, 860-77	24.4	476
170	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. <i>Journal of Thoracic Oncology</i> , 2015 , 10, S1-63	8.9	102
169	Objective measurement and clinical significance of TILs in non-small cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	232
168	A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. <i>BMC Cancer</i> , 2015 , 15, 171	4.8	36

167	Targeted Therapy in Solid Tumors: Lung Cancer 2015 , 224-230		
166	A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. <i>PLoS ONE</i> , 2015 , 10, e0122628	3.7	18
165	Lung cancer in the era of precision medicine. <i>Clinical Cancer Research</i> , 2015 , 21, 2213-20	12.9	109
164	Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. <i>Clinical Cancer Research</i> , 2015 , 21, 514-25	12.9	58
163	Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015 , 33, 952-63	2.2	80
162	Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. <i>Clinical Cancer Research</i> , 2015 , 21, 1514-24	12.9	165
161	Phase I Trials Today 2015 , 661-676.e2		
160	Lung-MAP--framework, overview, and design principles. <i>Chinese Clinical Oncology</i> , 2015 , 4, 36	2.3	20
159	Programmed death ligand-1 expression in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2014 , 94, 107-16	5.9	591
158	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 1407-20	6.4	28
157	American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1277-80	2.2	273
156	New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. <i>Clinical Cancer Research</i> , 2014 , 20, 4425-35	12.9	21
155	A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 3921-30	12.9	66
154	AACR celebrates 50 years of tobacco research and policy. <i>Clinical Cancer Research</i> , 2014 , 20, 1709-18	12.9	
153	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014 , 515, 563-7	50.4	3354
152	B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. <i>Cancer Journal (Sudbury, Mass)</i> , 2014 , 20, 281-9	2.2	52
151	"Companion diagnostics": has their time come and gone?. <i>Clinical Cancer Research</i> , 2014 , 20, 4422-4	12.9	14
150	"Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. <i>Clinical Cancer Research</i> , 2014 , 20, 301-9	12.9	51

149	Angiogenesis inhibition and lung-cancer therapy. <i>Lancet Oncology, The</i> , 2014 , 15, 124-5	21.7	5
148	Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. <i>Clinical Lung Cancer</i> , 2014 , 15, 379-86	4.9	9
147	A step towards treating KRAS-mutant NSCLC. <i>Lancet Oncology, The</i> , 2013 , 14, 3-5	21.7	3
146	Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. <i>Cancer Cytopathology</i> , 2013 , 121, 500-7	3.9	52
145	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , 2013 , 19, 279-90	12.9	649
144	Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. <i>European Journal of Cancer</i> , 2013 , 49, 1815-24	7.5	17
143	Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. <i>Clinical Cancer Research</i> , 2013 , 19, 1941-8	12.9	143
142	CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. <i>Cancer Research</i> , 2013 , 73, 571-82	10.1	114
141	Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. <i>Clinical Cancer Research</i> , 2013 , 19, 6967-75	12.9	49
140	Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 140-6	8.9	18
139	Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1519-28	8.9	18
138	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS8118-TPS8118	11.8	4
137	Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1137-9	2.2	6
136	Small-cell lung cancer: prognostic factors and changing treatment over 15 years. <i>Clinical Lung Cancer</i> , 2012 , 13, 115-22	4.9	69
135	Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. <i>Clinical Cancer Research</i> , 2012 , 18, 638-44	12.9	34
134	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 228-39	9.7	331
133	Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2869-75	2.2	36
132	Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. <i>Clinical Cancer Research</i> , 2012 , 18, 4004-12	12.9	40

131	Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. <i>Clinical Cancer Research</i> , 2012 , 18, 1641-54	12.9	45
130	Methodological and practical challenges for personalized cancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 135-41	19.4	138
129	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2011 , 377, 1846-54	4.0	317
128	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1313-28	15.9	124
127	Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). <i>Investigational New Drugs</i> , 2011 , 29, 499-505	4.3	15
126	The BATTLE trial: personalizing therapy for lung cancer. <i>Cancer Discovery</i> , 2011 , 1, 44-53	24.4	660
125	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2312-8	2.2	132
124	Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. <i>Cancer Research</i> , 2011 , 71, 5512-21	19.1	48
123	Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2839-46	2.2	346
122	Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 859-65	9.7	57
121	Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4747-54	2.2	57
120	Tobacco and cancer: an American Association for Cancer Research policy statement. <i>Cancer Research</i> , 2010 , 70, 3419-30	10.1	45
119	A first-in-human study of conatumumab in adult patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 5883-91	12.9	109
118	VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. <i>Lung Cancer</i> , 2010 , 69, 337-40	5.9	44
117	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2010 , 11, 619-26	21.7	364
116	A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1054-9	8.9	72
115	Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 940-9	8.9	39
114	Integration of molecular profiling into the lung cancer clinic. <i>Clinical Cancer Research</i> , 2009 , 15, 5317-22	12.9	73

113	Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3600-9	12.9	81
112	Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3557-65	2.2	225
111	Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. <i>Clinical Lung Cancer</i> , 2009 , 10, 20-7	4.9	16
110	Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. <i>Clinical Lung Cancer</i> , 2009 , 10, 392-4	4.9	16
109	Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2009 , 10, 13-19	4.9	
108	A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2009 , 115, 1713-22	6.4	31
107	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 467-76	4.9	9
106	Patient selection criteria and the FLEX Study. <i>Lancet, The</i> , 2009 , 373, 1497-8	4.0	4
105	Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. <i>Journal of Computer Assisted Tomography</i> , 2009 , 33, 460-5	2.2	21
104	Multitargeted inhibitors in lung cancer: new clinical data. <i>Clinical Lung Cancer</i> , 2008 , 9 Suppl 3, S92-9	4.9	6
103	Lung cancer. <i>New England Journal of Medicine</i> , 2008 , 359, 1367-80	59.2	1920
102	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1472-8	2.2	257
101	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5407-15	2.2	198
100	Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. <i>Oncologist</i> , 2008 , 13, 1166-76	5.7	39
99	Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 517-23	8.9	74
98	Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1135-41	2.2	63
97	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3351-7	2.2	249
96	Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. <i>Clinical Trials</i> , 2008 , 5, 181-93	2.2	149

95	Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 351-7	8.9	56
94	Advances in the Treatment of Metastatic Non-Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. <i>Clinical Pulmonary Medicine</i> , 2008 , 15, 352-358	0.3	
93	To kill a tumor cell: the potential of proapoptotic receptor agonists. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1979-90	15.9	247
92	Phase 1 Trials Today 2008 , 553-570		
91	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 239-49	5.9	112
90	Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2652-63	6.1	32
89	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4270-7	2.2	254
88	Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4743-50	2.2	357
87	Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 870-8	4	41
86	Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 1534-43	4	46
85	2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006. <i>Clinical Lung Cancer</i> , 2007 , 8, 234-241	4.9	
84	Phase I participants' views of quality of life and trial participation burdens. <i>Supportive Care in Cancer</i> , 2007 , 15, 885-90	3.9	20
83	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 471-83	6.1	76
82	Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6175-81	12.9	78
81	Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2369-76	2.2	173
80	Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, s4641-6	12.9	29
79	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2890-6	12.9	527
78	PD3-3-4: Vandetanib in advanced NSCLC: an ongoing clinical evaluation program. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S467-S468	8.9	2

77	Use of novel second-line targeted therapies in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2006 , 33, S9-16	5.5	21
76	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. <i>Clinical Lung Cancer</i> , 2006 , 7, 326-31	4.9	27
75	Toxicities of antiangiogenic therapy in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2006 , 8 Suppl 1, S23-30	4.9	41
74	Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2006 , 24, 190-205	2.2	95
73	Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. <i>Clinical Cancer Research</i> , 2006 , 12, 3408-15	12.9	44
72	Therapeutic options to target angiogenesis in human malignancies. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 635-50	3.7	63
71	Molecular targeted therapy for lung cancer. <i>Lancet, The</i> , 2005 , 366, 1507-8	4.0	7
70	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8081-92	2.2	551
69	Angiogenesis and lung cancer: prognostic and therapeutic implications. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3243-56	2.2	207
68	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5900-9	2.2	1250
67	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5892-9	2.2	1267
66	Current management of advanced non-small cell lung cancer: targeted therapy. <i>Seminars in Oncology</i> , 2005 , 32, 315-28	5.5	39
65	Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2946-54	2.2	97
64	Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. <i>Radiology</i> , 2005 , 237, 342-7	20.5	71
63	Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5578-87	2.2	337
62	Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5464-73	2.2	249
61	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2544-55	2.2	497
60	Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5474-83	2.2	421

59	Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9089-96 ^{2,2}	141
58	Angiogenesis pathway inhibitors. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005 , 22, 225-45	2
57	Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. <i>Clinical Cancer Research</i> , 2005 , 11, 678-89	12.9 27
56	Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 136-43	12.9 132
55	Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. <i>Clinical Cancer Research</i> , 2004 , 10, 33-42	12.9 36
54	Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 8613-9	12.9 17
53	Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. <i>Journal of Clinical Oncology</i> , 2004 , 22, 785-94	2.2 1508
52	Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2184-91	2.2 1682
51	Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?. <i>Oncologist</i> , 2004 , 9 Suppl 1, 19-26	5:7 56
50	Gefitinib--a novel targeted approach to treating cancer. <i>Nature Reviews Cancer</i> , 2004 , 4, 956-65	31.3 283
49	Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. <i>Clinical Lung Cancer</i> , 2004 , 6 Suppl 1, S7-S19	4.9 29
48	Review of epidermal growth factor receptor biology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 59, 21-6	4 859
47	Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 308-14	3.5 35
46	Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. <i>Cancer</i> , 2004 , 101, 1733-44	6.4 7
45	Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. <i>Lung Cancer</i> , 2004 , 44, 99-110	5.9 100
44	Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. <i>Clinical Lung Cancer</i> , 2004 , 5 Suppl 2, S67-74	4.9 6
43	Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. <i>Journal of Clinical Oncology</i> , 2004 , 22, 777-84	2.2 1496
42	Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4258s-4262s	12.9 87

41	Imaging in drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2004 , 2, 268-9	0.6	2
40	EGFR inhibition in NSCLC: the emerging role of cetuximab. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004 , 2 Suppl 2, S41-51	7.3	
39	Antiangiogenic tumor therapy. <i>BioTechniques</i> , 2003 , 34, 1048-50, 1052, 1054 passim	2.5	11
38	The role of growth factor signaling in malignancy. <i>Cancer Treatment and Research</i> , 2003 , 115, 19-72	3.5	13
37	Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. <i>Seminars in Oncology</i> , 2003 , 30, 30-8	5.5	35
36	Integration of targeted therapies in gemcitabine chemotherapy regimens. <i>Clinical Lung Cancer</i> , 2003 , 4, 217-23	4.9	2
35	Dermatologic side effects associated with gefitinib therapy: clinical experience and management. <i>Clinical Lung Cancer</i> , 2003 , 4, 366-9	4.9	91
34	The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. <i>Seminars in Oncology</i> , 2003 , 30, 113-23	5.5	12
33	Erlotinib (Tarceva): An update on the clinical trial program. <i>Seminars in Oncology</i> , 2003 , 30, 34-46	5.5	63
32	Mode of action of docetaxel - a basis for combination with novel anticancer agents. <i>Cancer Treatment Reviews</i> , 2003 , 29, 407-15	14.4	171
31	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 2149-58	27.4	2093
30	Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2574-82	2.2	381
29	A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 4108-15	12.9	33
28	Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. <i>Clinical Cancer Research</i> , 2003 , 9, 5532-9	12.9	117
27	Targeting the epidermal growth factor receptor in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 5813-24	12.9	78
26	Gefitinib: current and future status in cancer therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003 , 1, 466-72	0.6	14
25	Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2002 , 3 Suppl 1, S30-8	4.9	17
24	Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. <i>Seminars in Oncology</i> , 2002 , 29, 27-36	5.5	167

23	Angiogenesis inhibitors in clinical development for lung cancer. <i>Seminars in Oncology</i> , 2002 , 29, 66-77	5.5	43
22	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. <i>Cancer</i> , 2002 , 94, 1593-611	6.4	391
21	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. <i>Cancer</i> , 2002 , 95, 340-53	6.4	29
20	Angiogenesis inhibitors in lung cancer. <i>Current Oncology Reports</i> , 2002 , 4, 325-33	6.3	9
19	ZD1839: targeting the epidermal growth factor receptor in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 837-49	5.9	50
18	Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3804-14	2.2	172
17	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3815-25	2.2	504
16	Phase I study of recombinant human endostatin in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3792-803	2.2	256
15	Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3785-91	2.2	47
14	Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4440-7	2.2	89
13	ZD1839 (Iressa) in non-small cell lung cancer. <i>Oncologist</i> , 2002 , 7 Suppl 4, 9-15	5.7	287
12	Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. <i>Lung Cancer</i> , 2002 , 37, 17-27	5.9	26
11	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. <i>Seminars in Oncology</i> , 2002 , 29, 18-30	5.5	60
10	Targeted therapy in non-small-cell lung cancer. <i>Oncology</i> , 2002 , 16, 19-24	1.8	18
9	Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 151-9	3.5	27
8	Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. <i>Current Oncology Reports</i> , 2001 , 3, 131-40	6.3	39
7	Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2001 , 92, 2364-73	6.4	43
6	ZD1839 (Iressa) in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2001 , 3, 27-32	4.9	13

5	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2001 , 1, 719-32	5.4	82
4	Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. <i>American Journal of Pathology</i> , 2000 , 157, 1893-903	5.8	130
3	Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 41, 497-504	3.5	59
2	Chemotherapy for advanced non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 1997 , 11, 473-517	3.1	14
1	Tyrosine-kinase inhibitors in oncology872-883		